Evaluation of Celiac Disease by Minimally Invasive Biomarkers in a Spanish Pediatric Population

Background: The diagnosis of celiac disease (CD) has been substantially improved with the availability of highly sensitive CD-specific IgA-TG2, Ig-GDP, and IgA-EMA. The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) published (2012) and updated (2020) diagnostic...

Descripción completa

Detalles Bibliográficos
Autores: Cabo del Riego, Julia María, Núñez Iglesias, María Jesús, García-Plata González, Carmen, Paz Carreira, José, Álvarez Fernández, Tamara, Dorado Díaz, Ana, Villar Mallo, Noa, Penedo Pita, Manuel, Novío Mallón, Silvia, Máiz Suárez, Lola, Freire-Garabal Núñez, Manuel
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Santiago de Compostela (USC)
Repositorio:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Idioma:inglés
OAI Identifier:oai:minerva.usc.gal:10347/43327
Acceso en línea:https://hdl.handle.net/10347/43327
Access Level:acceso abierto
Palabra clave:Non-invasive biomarkers
Celiac disease
ESPGHAN
Diagnosis
Antibodies
Pediatric age
Descripción
Sumario:Background: The diagnosis of celiac disease (CD) has been substantially improved with the availability of highly sensitive CD-specific IgA-TG2, Ig-GDP, and IgA-EMA. The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) published (2012) and updated (2020) diagnostic criteria for CD in order to simplify CD diagnosis and to avoid biopsies in selected patients. Methods: A prospective study including 5641 pediatric patients (0–16 years old) from January 2012 to January 2019 was performed. CD diagnosis was made according to the ESPGHAN algorithm. The objective of this study was to evaluate the utility of biomarkers and the relationship between TGA-IgA and EMA titers. Results: CD diagnoses were confirmed in 113 patients, 110 were IgA-TG2-positive and 3 (2.7%) had IgA deficiency. The diagnosis was made by serologic tests in 95 (84.1%) patients. Only 18 (15.9%) patients underwent intestinal biopsy. We obtained 100% concordance between IgA-EMA and positive results for IgA-TG2 ≥ 10 ULN with IgAEMA antibody titer ≥1:80. Conclusions: This study provides evidence of a positive correlation between IgA-TG2 antibody serum levels and IgA-EMA. The diagnosis could be guaranteed with strict application of IgA-TG2 values ≥10 ULN (confirmed by subsequent testing) plus the serological response to the gluten-free diet (GFD).

Similares en LA Referencia